Core Points - The company N建发致 was listed today with an opening price of 36.00 yuan, reflecting a significant increase of 410.64% from its issue price [2] - The company primarily engages in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [2] - The total number of shares issued by the company is 63.19 million, with an online issuance of 20.85 million shares at an issue price of 7.05 yuan per share, resulting in a price-to-earnings ratio of 13.29, which is lower than the industry average of 25.73 [2] - The effective subscription number for the online issuance reached 13.47 million accounts, with a final winning rate of approximately 0.0198% [2] - The funds raised from the initial public offering (IPO) amount to 446 million yuan, which will be allocated to enhance working capital, upgrade information systems, and support centralized operation services for medical consumables [2] Recent IPO Performance - N建发致 (301584) was listed on September 25, 2025, with an issue price of 7.05 yuan and a first-day opening increase of 410.64% in the pharmaceutical and biological industry [2] - Other recent IPOs on the same day include N联合动 (301656) with a first-day increase of 174.04% and N锦华 (920015) with a first-day increase of 114.88%, indicating strong market interest in new listings [2][3] - The performance of newly listed stocks shows significant first-day price increases across various sectors, highlighting a trend of investor enthusiasm for IPOs [2][3]

Group 1 - The core viewpoint of the article is that Jianfa Zhixin (301584.SZ) has officially listed on the A-share market, experiencing a significant intraday increase of 427.94%, reaching a price of 37.22 yuan [1] - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to end hospitals [1] - The IPO price was set at 7.05 yuan per share, with a total of 63.1933 million shares issued, raising funds mainly for the upgrade of information systems and centralized operation services for medical consumables [1] Group 2 - The implementation of the projects funded by the IPO is expected to significantly enhance the company's information system support capabilities, improve refined and intelligent operational levels, and provide a solid technical foundation for the continuous expansion of business scale and efficient management [1] - Analysts indicate that by deeply integrating information management with traditional medical device distribution, Jianfa Zhixin has developed into one of the leading companies in the domestic high-value medical device distribution sector [1] - Post-listing, the company is expected to further strengthen its competitive advantage in the industry and consolidate its market position, leveraging the resources of Xiamen Jianfa Group and its state-owned background [1]

Core Viewpoint - Five companies listed on the ChiNext board have announced their performance forecasts for the first three quarters, all indicating an increase in profits [1] Group 1: Company Performance Forecasts - Changchuan Technology (300604) expects a net profit increase of 138.39% with a latest closing price of 96.32 yuan and a year-to-date increase of 118.75% [1] - Zhongtai Co., Ltd. (300435) anticipates a net profit increase of 79.28%, with a latest closing price of 21.85 yuan and a year-to-date increase of 83.52% [1] - N United (301656) forecasts a net profit increase of 44.16% [1] - N Jianda (301584) projects a net profit increase of 35.00% [1] - Aifen Dazhi (301575) expects a net profit increase of 14.72%, with a latest closing price of 55.40 yuan and a year-to-date decrease of 25.91% [1] Group 2: Industry Insights - The companies span various industries, including electronics, public utilities, automotive, pharmaceuticals, and light manufacturing [1]

Core Viewpoint - The recent listings of Jianfa Zhixin, United Power, and Jinhua New Materials on the stock exchanges highlight the growth and investment opportunities in the medical device and new energy sectors in China [1][2]. Group 1: Jianfa Zhixin - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution, providing centralized operation services for medical consumables to hospitals [1]. - The company has a market capitalization of 2.97 billion yuan, with an issuance price of 7.05 yuan per share and a P/E ratio of 13.29, significantly lower than the industry average of 25.73 [2]. - In 2024, Jianfa Zhixin's revenue is projected to be divided into three segments: direct sales (11.03 billion yuan, 61.69%), distribution (6.74 billion yuan, 37.68%), and services (112 million yuan, 0.63%) [4]. - The company plans to invest 1.4 billion yuan in information system upgrades, 1.04 billion yuan in centralized operation services, and 2.4 billion yuan to supplement working capital [3]. Group 2: United Power - United Power, spun off from the industrial automation giant Inovance Technology, specializes in new energy vehicle power systems, including electric drive and power supply systems [6][7]. - The company is a leader in the new energy vehicle power system sector, providing solutions to over 40 vehicle manufacturers and participating in the entire lifecycle of vehicle design and production [7]. - United Power's accounts receivable have increased significantly, with values of 1.85 billion yuan, 3.61 billion yuan, and 5.68 billion yuan from 2022 to 2024, representing 20.37%, 29.38%, and 31.45% of total assets respectively [8]. Group 3: Jinhua New Materials - Jinhua New Materials focuses on the research, production, and sales of ketoxime series fine chemicals, being a leader in the domestic silane crosslinking agent market with market shares of 27.85%, 31.60%, and 38.16% from 2022 to 2024 [9]. - The company's products are essential for various industries, including construction, energy, electronics, and new energy vehicles [9]. - Jinhua New Materials has received multiple national honors and has participated in the formulation of several industry standards [9].

Group 1: Company Listings - Jianfa Zhixin (建发致新) and United Power (联合动力) were listed on the Shenzhen Stock Exchange, while Jinhua New Materials (锦华新材) was listed on the Beijing Stock Exchange [1] Group 2: Jianfa Zhixin (建发致新) - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, and provides centralized operation services for medical consumables to hospitals [2] - The company raised a total of 445.51 million yuan, with a net amount of 363.33 million yuan after deducting issuance costs, which will be used for information system upgrades, centralized operation services for medical consumables, and to supplement working capital [2] Group 3: United Power (联合动力) - United Power aims to become a global leader in intelligent electric vehicle components and solutions, with main products including electric drive systems and power systems [3] - The company raised a total of 360.14 million yuan, with a net amount of 353.21 million yuan after deducting issuance costs, which will be allocated to the production of core components for new energy vehicles, R&D center construction, digital system development, and to supplement operating funds [4] Group 4: Jinhua New Materials (锦华新材) - Jinhua New Materials focuses on the R&D, production, and sales of ketoxime series fine chemicals, with main products including silane crosslinking agents and hydroxylamine salts [5] - The company raised a total of 59.29 million yuan, with a net amount of 54.91 million yuan after deducting issuance costs, which will be used for a high-end coupling agent project, a pilot project, and the construction of an intelligent factory for the ketoxime industry chain [5]

Core Insights - Three companies have recently been listed on different stock exchanges, with their respective issuance prices and price-earnings ratios provided [1][2][3][4]. Group 1: Company Listings - Jianfa Zhixin was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301584, an issuance price of 7.05 CNY per share, and a price-earnings ratio of 13.29 [2]. - United Power was listed on the Shenzhen Stock Exchange's ChiNext with a stock code of 301656, an issuance price of 12.48 CNY per share, and a price-earnings ratio of 32.87 [3]. - Jinhua New Materials was listed on the Beijing Stock Exchange with a stock code of 920015, an issuance price of 18.15 CNY per share, and a price-earnings ratio of 11.95 [4]. Group 2: Company Profiles - Jianfa Zhixin specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [2]. - United Power aims to be a global leader in intelligent electric vehicle components and solutions, focusing on core components of power systems such as electric drive systems and power supply systems [3]. - Jinhua New Materials is engaged in the research, production, and sales of ketoxime series fine chemicals [5].

Market Overview - On September 24, 2025, A-shares saw all three major indices close higher, with the Shanghai Composite Index at 3853.64 points, up 0.83% [1] - The Shenzhen Component Index closed at 13356.14 points, up 1.80%, and the ChiNext Index at 3185.57 points, up 2.28% [1] - The total trading volume in the Shanghai and Shenzhen markets was 2.33 trillion yuan, a decrease of 160 billion yuan from the previous trading day [1] - Hong Kong stocks opened lower but rose throughout the day, with the Hang Seng Index closing at 26518.65 points, up 1.37% [1] - The total trading volume in Hong Kong was 288.77 billion HKD [1] - In contrast, U.S. stocks closed lower, with the Dow Jones down 0.37% at 46,121.28 points, and the S&P 500 down 0.28% at 6,637.97 points [1] New Stock Listings - Two new stocks were listed today: - Jianfa Zhixin, with a price of 7.05 yuan per share and a P/E ratio of 13.29, operates a national medical device supply chain platform [2] - United Power, priced at 12.48 yuan per share with a P/E ratio of 32.87, focuses on the development and production of electric drive systems for new energy vehicles [2] Industry News - Eight departments, including the Ministry of Commerce, issued guidelines to boost digital consumption, encouraging innovation in AI terminal products and smart appliances [3] - The guidelines aim to enhance the supply of AI products and promote the development of smart connected vehicles [3] - Six departments announced strict controls on the production capacity of cement and flat glass, prohibiting new capacity and requiring capacity replacement plans for new projects [4] - The measures aim to eliminate outdated production capacity and promote environmental standards in the construction materials industry [4] - Nine departments, including the Ministry of Commerce, supported the establishment of international data centers and cloud computing centers in free trade zones and pilot areas [5][6]

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. has received approval for its initial public offering (IPO) of A-shares on the ChiNext board, with the issuance price set at RMB 7.05 per share [1][2]. Group 1: Issuance Details - The total number of shares to be issued is 63,193,277 shares, with a strategic placement involving both institutional and retail investors [2][3]. - The strategic placement will consist of 6,300,000 shares allocated to employee asset management plans, accounting for approximately 9.97% of the total issuance [3]. - The initial strategic placement was set at 12,638,655 shares (20.00% of total), but the final amount was adjusted to 9,478,992 shares (15.00%) due to a reallocation to offline issuance [3][4]. Group 2: Subscription and Allocation - The offline initial issuance quantity was 43,603,785 shares, representing 81.18% of the total issuance after deducting the final strategic placement [4]. - The online initial issuance quantity was 10,110,500 shares, accounting for 18.82% of the total issuance [4]. - The final subscription rate for the online issuance was 0.0198%, with a subscription multiple of 5,038.48 times [4]. Group 3: Payment and Lock-up Period - Investors must complete payment for their subscriptions by September 18, 2025, to ensure their allocations remain valid [5][6]. - Online issuance shares will have no restrictions on circulation, while offline shares will have a 10% lock-up period of 6 months [7]. - Strategic placement investors will face a 12-month lock-up period starting from the listing date [7][8].

１、网上投资者申购新股中签后，应根据本公告履行资金交收义务，确保其资金账户在２０２５年９月 １８日（Ｔ＋２日）日终有足额的新股认购资金，不足部分视为放弃认购，由此产生的后果及相关法律 责任由投资者自行承担。投资者款项划付需遵守投资者所在证券公司的相关规定。 网上投资者放弃认购的股份由保荐人（主承销商）包销。 登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 敬请投资者重点关注本次发行的缴款环节，并于２０２５年９月１８日（Ｔ＋２日）及时履行缴款义 务，具体内容如下： ２０２５年９月１８日 ■ 凡参与本次网上定价发行申购建发致新Ａ股股票的投资者持有的申购配号尾数与上述号码相同的，则为 中签号码。中签号码共有４１，７０７个，每个中签号码只能认购５００股建发致新Ａ股股票。 发行人：上海建发致新医疗科技集团股份有限公司 保荐人（主承销商）：中信证券股份有限公司 ２、本次发行的股票中，网上发行的股票无流通限制及限售期安排，自本次公开发行的股票在深圳证券 交易所上市之日起即可流通。 ４、网上投资者连续１２个月内累计出现３次中签后未足额缴款的情形时，自结算参与人最近一次申报 其放弃认购的次日起６个月（按１８０个自然 ...

医疗器械流通行业正经历深刻变革。 当集采常态化压缩中间环节利润、DRG/DIP医保支付改革倒逼医院控费增效时，传统多级分销模式已无法匹配产业升 级需求，资源整合能力与精细化服务正成为行业新竞争内核。 此背景下，国内领先的高值医疗器械流通商——建发致新（301584.SZ），已于近期启动创业板证券发行工作。依托 于覆盖全国的直销及分销网络、自主开发的医用耗材集约化运营（SPD）管理系统，以及从厂商到医院的一体化服务 模式，建发致新已然成为医疗器械流通行业重塑浪潮中的有力领跑者。 不妨就此来深度剖析其背后的业务韧性与成长逻辑。 产业变局：政策重塑与效率革命，踏准发展脉搏 按自上而下的投资逻辑审视，医疗器械流通行业在供需双侧的政策变革推动下，正从单纯的物流中转站升级为供应链 价值整合者。 于供给端，两票制与集采深化持续压缩流通环节。 随着产业链的深度整合成为必然，上下游整合加速，建发致新这类兼具渠道广度、服务深度与数字化能力的流通平 台，正在成为提升整个医疗器械供应链效率和服务质量的关键节点。 核心优势：构建立体壁垒，多维度彰显成长性 例如，国家《治理高值医用耗材改革方案》推行的"两票制"有效减少了流通层级，显著降 ...